Related Experiment Video
Updated: Feb 8, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
Cellular Context Influences Kinase Inhibitor Selectivity
Matthew J Binder1, Frances M Bashore1, Kaitlin K Dunn Hoffman2
1Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Abstract:
A pivotal part of kinase chemical probe and drug development is assessment of the selectivity of a putative lead compound. While there is no consensus around the panel size or the type of assay(s) that are most appropriate, there is concurrence that gauging the number of on- and off-targets of a kinase inhibitor is essential. As pharmacology takes place in cells, we have compared profiling results for ten kinase inhibitors generated using the cell-free assays to those obtained when a panel of cellular target engagement NanoBRET assays is used to assess selectivity in intact cells. This is the first systematic comparison of these two approaches across a broad kinase panel. Comparison of the data sets demonstrates divergent results that can influence chemical probe prioritization. We identify unanticipated kinase interactions in cells for type II kinase inhibitors that are not observed in biochemical, cell-free systems. Furthermore, we characterize TPKI-39 as a DDR1, DDR2, and FLT1 chemical probe based on its in-cell selectivity profile.
Insights
Assessing kinase inhibitor selectivity in cells using NanoBRET assays reveals crucial on- and off-target interactions missed by cell-free methods, impacting chemical probe development.
Area of Science:
- Biochemistry
- Pharmacology
- Chemical Biology
Background:
- Kinase inhibitor selectivity profiling is essential for chemical probe and drug development.
- Gauging the number of on- and off-targets for kinase inhibitors is critical.
- Cellular pharmacology necessitates in-cell assessment of target engagement.
Purpose of the Study:
- To systematically compare cell-free kinase inhibitor profiling with in-cell target engagement NanoBRET assays.
- To evaluate how different assay types influence chemical probe prioritization.
- To identify kinase interactions specific to cellular environments.
Main Methods:
- Profiling ten kinase inhibitors using both cell-free and cellular NanoBRET assays across a broad kinase panel.
- Comparing selectivity profiles obtained from biochemical assays versus intact-cell assays.
- Characterizing TPKI-39's in-cell selectivity profile.
Main Results:
- Divergent selectivity profiling results were observed between cell-free and in-cell assays.
- Unanticipated kinase interactions for type II kinase inhibitors were identified in cells but not in cell-free systems.
- TPKI-39 was characterized as a chemical probe for DDR1, DDR2, and FLT1 based on its in-cell selectivity.
Conclusions:
- In-cell target engagement assays provide a more accurate assessment of kinase inhibitor selectivity compared to cell-free methods.
- Cellular context reveals kinase interactions missed by biochemical assays, influencing chemical probe selection.
- TPKI-39 demonstrates specific in-cell activity, validating its use as a chemical probe for DDR1, DDR2, and FLT1.
Related Concept Videos
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
Self Within Cultural Contexts
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Frequency-dependent Selection

